Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety Study of BMS-986205 in Combination With Nivolumab in Advanced Malignant Tumors
jRCT2080223603Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linrodostat and nivolumab in Non-hematologic malignancy, sponsored by Bristol Myers Squibb. Primary endpoint: Primary safety and tolerability. Started Jul 2017; status: completed.
02
Drugs
linrodostatnivolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223603.